0 reactions
indianmarketgrid The US approval broadens tirzepatide beyond glucose control after a head-to-head trial showed fewer major heart events than Trulicity.
READ FULL ANALYSIS MEMBER ANALYSIS
THE IMG COMMUNITY
Market insights. Fresh perspectives. Your conversation.
indianmarketgrid The US approval broadens tirzepatide beyond glucose control after a head-to-head trial showed fewer major heart events than Trulicity.